National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, National Cancer Policy Forum, Forum on Drug Discovery, Development, and Translation, Carolyn Shore...
Despite decades of ongoing efforts to improve racial and ethnic diversity in clinical trials, many gaps remain in achieving demographic representation in clinical studies. In May 2024, the National Academies Forum on Drug Discovery, Development, and...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Board on Health Care Services, National Cancer...
The use of immune modulator therapeutics, a type of immunotherapy enhancing the body immune system response to cancer, was perceived as the beginning of a new era in cancer care. While still important and frequently used, some of these therapeutics...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Carolyn Shore, Kyle Cavagnini...
The proper disposal of unused or expired prescription drugs, particularly controlled substances such as opioids, may help to prevent serious risk of nonmedical use or overdose. In June 2023, the National Academies Forum on Drug Discovery, Developmen...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Carolyn Shore, Andrew March...
Approximately 4 million pregnant people in the United States give birth annually, and 70 percent of these individuals take at least one prescription medication during their pregnancy. Yet, due to a number of historical, ethical, legal, scientific, a...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Carolyn Shore, Amanda Wagner Gee...
The evolution of health care is expanding the possibilities for integration of clinical research into the continuum of clinical care; new approaches are enabling the collection of data in real-world settings; and new modalities, such as digital heal...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Carolyn Shore, Robert Pool...
Examines the steps involved in developing treatments for cancer. The recommendations in this book are offered to organisations such as the National Cancer Institute and the pharmaceutical and biotechnology industries and others, who bear responsibil...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, Forum on Drug Discovery, Development, and Translation, Carolyn S...
On March 24, 2020, a 1-day public workshop titled The Role of Digital Health Technologies in Drug Development was convened by the National Academies of Sciences, Engineering, and Medicine. This workshop builds on prior efforts to explore how virtual...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Carolyn Shore, Eeshan Khandekar...
Successful drug development relies on accurate and efficient clinical trials to deliver the best and most effective pharmaceuticals and clinical care to patients. However, the current model for clinical trials is outdated, inefficient and costly. Cl...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Carolyn Shore, Amanda Wagner Gee...
Randomized controlled trials (RCTs) have traditionally served as the gold standard for generating evidence about medical interventions. However, RCTs have inherent limitations and may not reflect the use of medical products in the real world. Additi...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, Forum on Drug Discovery, Development, and Translation, Sarah H. B...
Those involved in the drug development process face challenges of efficiency and overall sustainability due in part to high research costs, lengthy development timelines, and late-stage drug failures. Novel clinical trial designs that enroll partici...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Anne B. Claiborne, Amanda Wagner Gee...
The volume and complexity of information about individual patients is greatly increasing with use of electronic records and personal devices. Potential effects on medical product development in the context of this wealth of real-world data could be...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Roundtable on Genomics and Precision Health, Sarah H. B...
The process of discovering and developing a new drug or therapy is extremely costly and time consuming, and recently, it has been estimated that the creation of a new medicine costs on average more than 2 billion and takes 10 years to reach patient...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Anne B. Claiborne, Amanda Wagner Gee...
The field of endeavors known as regulatory science has grown out of the need to link and integrate knowledge within and among basic science research, clinical research, clinical medicine, and other specific scientific disciplines whose focus, aggr...Loe edasi...
National Academies of Sciences, Engineering, and Medicine, Institute of Medicine, Board on Global Health, Board on Health Sciences Policy, Forum on Microbial Threats, Forum on Drug Discovery, Development, and Translation...
Emerging infectious disease threats that may not have available treatments or vaccines can directly affect the security of the worlds health since these diseases also know no boundaries and will easily cross borders. Sustaining public and private i...Loe edasi...
Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Forum on Neuroscience and Nervous System Disorders, Clare Stroud, Christopher DeFeo, Evelyn Strauss, Sheena M. Posey Norris...
The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might...Loe edasi...
Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Anne B. Claiborne, Rebecca A. English, Denise Caruso
Despite the extensive body of evidence that informs regulatory decisions on pharmaceutical products, significant uncertainties persist, including the underlying variability in human biology, factors associated with the chemistry of a drug, and limit...Loe edasi...
Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine, Steve Olson, Rebecca A. English, Anne B. Claiborne
Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. This book presents the summary of a worksho...Loe edasi...
Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine, Steve Olson, Rebecca A. English, Anne B. Claiborne
(Ilmumisaeg: 28-Feb-2014, Hardback, Kirjastus: National Academies Press, ISBN-13: 9780309387705)
saadame teile pakkumise kasutatud raamatule, mille hind võib erineda kodulehel olevast hinnast
Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discove...Loe edasi...
Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Roundtable on Value and Science-Driven Health Care, Rebecca A. English, Julia Sanders, Claudia Grossmann
Presents the summary of a workshop convened by the Institute of Medicines Roundtable on Value & Science-Driven Health Care and the Forum on Drug Discovery, Development, and Translation....Loe edasi...
To explore the need and prospects for greater international regulatory harmonization for drug development, the IOM Forum on Drug Discovery, Development, and Translation hosted a workshop on February 13-14, 2013. This document summarizes the workshop...Loe edasi...
